Abeta 42 Antibody

Product Discontinued

Abeta 42 Antibody Summary

• Immunogen: This polyclonal antibody was raised by immunizing rabbit with a synthetic peptide containing 1-40 amino acids of amyloid.
• Specificity: Amyloid beta (37-42)
• Clonality: Polyclonal
• Host: Rabbit
• Gene: APP
• Purity: Immunogen affinity purified

Applications/Dilutions

• Dilutions:
  • Dot Blot
  • Western Blot
• Application Notes: The antibody specificity was assayed by dot blot analysis with the synthetic Amyloid (1-40) peptide antigen and Western blot analysis. The antibody titer is more than 10K for Dot blot and 1,000X for Western blot analysis (data not shown). It has not been tested in the other applications. However, for the first testing, we recommend 1/5,000 dilution for ELISA, 1/1,000 dilution for Western blot analysis (WB) of recombinant protein, 1/400 dilution for tissue extracts or cell lysates, 1/100 dilution for immunohistochemistry (IHC) staining on frozen cryosections, 1/50 dilution for IHC staining on paraffin embedded sections.

Reactivity Notes

Chemical

Packaging, Storage & Formulations

• Storage: Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
• Buffer: No buffer
• Preservative: No Preservative
• Concentration: LYOPH
• Purity: Immunogen affinity purified
• Reconstitution Instructions: Please contact technical support for detailed reconstituion instruction.

Notes

Add diH20 for desired concentration.

Alternate Names for Abeta 42 Antibody

• Amyloid beta 42
• Beta-amyloid protein 42

Background

The amyloid beta peptide (A beta) is the main component of amyloid deposits found in the brain of patients afflicted with Alzheimer's disease. Brain to blood transport is believed to be a major determinant of the amount of amyloid beta protein (AbetaP) found in brain. Chronic brain hypoperfusion (CBH) initiates spatial memory loss in aging rats thus mimicking human mild cognitive impairment (MCI) and also increases A beta in the hippocampus. The memory and amyloid changes are preceded by NO upregulation in the hippocampus. These preliminary findings may be important in understanding, at least in part, the molecular mechanisms that precede memory impairment during chronic brain ischemia and as such, the pre-clinical stage leading to Alzheimer's disease.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: APP